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Genome-wide association studies (GWAS) and linkage studies have had only limited success in discovering 
genome-wide significantly linked regions or risk loci for diabetic nephropathy in individuals with type 1 
diabetes (T1D). As GWAS cohorts have grown, they have also included more documented and undocumented 
familial relationships. Here, we computationally inferred and manually curated pedigrees in a study cohort 
of more than 6,000 individuals with T1D and their non-diabetic relatives. We performed linkage study for 177 
pedigrees consisting of 452 individuals with T1D and their relatives using a genome- wide genotyping array 
with more than 300,000 SNPs and the PSEUDOMARKER software. The analysis resulted in genome-wide 
significant linkage peaks on eight chromosomal regions from five chromosomes (logarithm of odds 
[LOD]>3.3). The highest peak was localized at the HLA region on chromosome 6p, but whether the peak 
originates from T1D or diabetic nephropathy, remains ambiguous. Of the other significant peaks, the 
chromosome 4p22 region is localized on top of a gene associated with focal segmental glomerulosclerosis, 
ARHGAP24, suggesting that the gene may play a role in diabetic nephropathy as well. Furthermore, rare 
variants have been associated with diabetic nephropathy and chronic kidney disease near the 4q25 peak, 
localized on top of CCSER1.
Introduction 
Diabetic nephropathy (DN, diabetic kidney disease) is a microvascular complication of diabetes that causes 
progressive decline in kidney function. Approximately one third of individuals with type 1 diabetes (T1D) and 
half of the individuals with type 2 diabetes develop some degree of kidney function impairment (1). For a 
significant proportion of these individuals, DN eventually leads to severe impairment of kidney function, end-
stage renal disease (ESRD), that can only be treated with dialysis or a kidney transplant.  
Both genetic and environmental factors play a role in the development and progression of the disease. DN 
segregates in families with sibling recurrence risk of 2.3. Overall, genetic factors are thought to explain 
approximately one third of the DN risk in those with T1D, although after excluding static risk factors, e.g. sex, 
the genetics was shown to explain half of the disease risk (2; 3). 
Although up to twenty susceptibility genes and loci have been found for DN by recent Genome-Wide 
Association Studies (GWASs) with increasingly large sample sizes, much of the predicted genetic risk of the 
disease remains unexplained (4; 5). However, while GWASs are best powered to detect common variants, 
many common diseases also have rarer variants that affect the disease risk at the individual level even more 
than the common variants do (2). Traditional GWASs do not capture rare variants, and whole exome or 
genome sequencing of unrelated individuals would need considerable sample sizes to detect such rare and 
low frequency variants. Many of these variants may also be population specific, and using pedigree-based 
data, linkage methods may serve as a more efficient design for the initial variant discovery (6). 
Several previous linkage studies found a genome-wide significant or suggestive linkage peak on chromosome 
3q in Finnish and other populations (7). More recently, a significant linkage peak was found on chromosome 
22 in Danish, Finnish and French sibling pairs (8). However, these linkage peaks do not occur in overlapping 
regions with GWAS findings, and the genetic background of the findings remains largely unclear. 
Here we present a genetic linkage study performed in small pedigrees consisting of Finnish individuals with 
T1D and genotyped with a modern genome-wide genotyping chip that included additional exonic variants on 
top of common genome-wide variants. The related individuals were extracted from the GWAS data, and the 
pedigrees were built computationally based on the identity-by-descent matrix (IBD) of their genetic 
distances; the 2nd and 3rd degree relationships were manually assessed and confirmed to construct the 
pedigrees.  
Research Design and Methods 
Genotyping and Imputation 
In total, 6,152 participants, including individuals with T1D and their relatives, were genotyped on three 
batches with Illumina HumanCoreExome Bead arrays 12-1.0, 12-1.1, and 24-1.0 (Illumina, San Diego, CA, USA) 
at the University of Virginia. Genotyping, variant calling, quality control (QC) and imputation have been 
described earlier (9). Variants were called with zcall algorithm to optimize calling of rare SNPs. QC included 
removal of variants with low genotyping call rate, deviation from Hardy-Weinberg equilibrium, allele 
frequency difference >20% (MAF 5%) or allele frequency difference >5% (MAF>5%) with the 1000 Genomes 
EUR population. The human reference genome GRCh37 was used for genotype coordinates. 
A total of 6,019 individuals passed QC, when samples with genotyping rate <0.95, extreme heterozygosity, 
sample mix-ups and genetic outliers, were removed. After genotype quality control, phased haplotypes 
(SHAPEIT v2r837) of 316,899 SNPs were used for imputation with 1000 Genomes EUR phase 3 version 5, 
using Minimac3/Minimac3-omp v1.0.14 (10-12). 
Study Cohort 
At the Finnish Diabetic Nephropathy (FinnDiane) Study visit, each patient underwent a thorough clinical 
investigation as described earlier (13). Micro- or macroalbuminuria was defined based on the urinary albumin 
excretion rate (AER) in 2 out of 3 consecutive timed overnight or 24h urine collections as previously described 
(13). ESRD was defined as ongoing dialysis or the patient having received a kidney transplant. ESRD diagnosis 
year was verified from hospital records.  
Individuals with micro-, macroalbuminuria or ESRD were set as cases and those with normal AER for at least 
15 years were set as controls. We included individuals with T1D with diabetes onset before the age of 40, 
and insulin treatment started within one year of the diagnosis of diabetes. All participants gave their written 
consent for this study.  
Pedigrees 
Pedigrees were built based on the individuals’ pairwise genetic distances in the SNP data. KING software was 
used to compute the pairwise genetic distances (based on the proportion of alleles with IBD=0, IBD=1, and 
IBD=2) between the subjects in the genotypic data (14). Pairs of individuals with 3rd degree relationship or 
closer (IBD=0 < 1 −
1
25/2
, kinship coefficient > 
1
29/2
), were considered to the automatic inferring of the 
pedigrees with the PRIMUS software(15).   
As the IBD=0 and kinship coefficients may be highly similar between different types of 2nd and 3rd degree 
relative pairs, we only used the automatic pedigree construction methods for pedigrees with complete 
parent-offspring and full-sibling familial relations. We used the more distant relation predictions as a basis 
to search and verify the actual relationship types using multiple sources such as population registries, medical 
records and questionnaires. The 2nd degree relationships (representing either grandparent-grandchild pairs, 
avuncular pairs, or half-siblings) were labeled as avuncular, if the age difference between the subjects was 
more than 30 years (unlikely to be half-siblings) but less than 35 years (unlikely grandparent-grandchild pairs). 
Unconfirmed 2nd and 3rd degree familial relations were not added to the pedigrees, and the final pedigree 
structures were checked using the Pedcheck software for the general structure. PLINK was used to check the 
Mendelian error rate for SNPs (16; 17).  
Parametric Two-point Linkage Analysis 
The linkage analysis for the autosomal markers was performed with the PSEUDOMARKER software for the 
directly genotyped SNPs by using default parameters and recessive inheritance model, resembling affected 
sibling pairs model for concordant sibling pairs.  The frequency of phenocopies was 0 and a LOD-score of 3.3 
was considered as genome-wide significant threshold (18; 19). We subsequently ran the linkage analysis on 
imputed markers for ±1 Mbp from the genome-wide significant linkage peaks, except for the HLA region. The 
markers were limited to those with imputation quality r2 over 0.75. We also performed separate analysis with 
pedigrees with only discordant and concordant individuals for DN, along with complex trees that included at 
least one unaffected individual and two or more affected ones. We also performed an additional linkage 
analysis using the dominant inheritance model to confirm overlapping peaks in both models. 
HLA Allele Prediction and Validation of HLA Allele Imputation  
We have previously genotyped the HLA alleles for the DQA1, DQB1 and DRB1 genes for 4,279 FinnDiane study 
participants (20). As almost half of the individuals in the pedigrees did not have HLA alleles typed, we imputed 
the HLA alleles using SNP2HLA software based on GWAS data from the HLA-region and the Type 1 Diabetes 
Genome Consortium’s (T1DGC) reference genotype-HLA-allele panel (21). 
In silico eQTL and mQTL Mapping Using Public Datasets  
We performed an in silico eQTL study for markers with genome-wide significant linkage LOD-scores for DN 
by searching two databases with kidney eQTL data: Human Kidney eQTL Atlas and NephQTL (22). We also 
queried the GTEx database for eQTL changes on various tissues and methylation quantitative trait loci (mQTL) 
from the mQTLdb database for changes on CpG-island methylation in blood (23; 24).  
In silico Replication of Linkage Peaks 
Of the diabetic nephropathy studies thus far, the study by Salem et al. (2019) includes the highest number of 
individuals (n= 19,327). Therefore, to search for further evidence for replication of our linkage peaks we used 
the publicly available meta-analysis results of that study (https://t2d.hugeamp.org/datasets.html). Based on 
the phenotype similarity with the current study and the replication dataset, we used the albuminuria-based 
“all diabetic kidney disease” phenotype (micro- or macroalbuminuria or ESRD vs. normal AER). Of note, the 
data include also unrelated individuals from the current linkage study.   
Results 
Individual and Pedigree Characteristics 
Of the total of 177 pedigrees, more than half (n = 95) consisted of sibling pairs either concordant or discordant 
for DN. Furthermore, the dataset included 40 pedigrees with sibships and more complex relationship 
structures, resulting in a median pedigree size of three. A total of 263 subjects were affected DN cases (micro- 
or macroalbuminuria or ESRD) and 120 individuals with T1D had had normal AER for at least 15 years and 
were assigned as unaffected individuals. Of note, 57 individuals had either unknown DN status, or short 
disease duration, or they were non-diabetic parents of the included participants; these individuals were 
included in the families but with an unknown phenotype (Table 1). Nine of the complex pedigrees are 
described in Supplementary Figure 1. 
There were more males (59.6%) among the affected individuals, whereas 52.3% of the unaffected individuals 
were women (Table 2). As expected, the affected individuals had higher systolic and diastolic blood pressure 
and longer diabetes duration. They were also younger and had slightly higher HbA1c. 
Genome-Wide Linkage Analysis 
We performed the parametric two-point linkage analysis for the 177 pedigrees and exome chip marker data 
using PSEUDOMARKER software. The analysis resulted in genome-wide significant linkage peaks (LOD-score 
>3.3) on 2q24.3, 2q37.2, 4q21-22, 4q25, 6p21-22, 20q13.2 and 22q12.1 (Figure 1, Table 3, Supplementary 
Figure 2). The highest linkage peak occurred at the chromosome region 6p21–6p22, located at 22.7–45.2Mb, 
with LOD-score up to 7.33 and altogether 165 markers on the region exceeding the LOD≥3.3 (Supplementary 
Figure 3). The multiple linkage peaks on chromosomes 2 and 4 likely originate from separate genetic signals 
due to long distance between the regions with significant LOD-scores. The linkage analysis was also run for 
imputed genotypic data for each significant linkage peak (except HLA-region), starting 1Mb prior to the first 
genome-wide significant marker and ending 1Mb after the last significant marker. The imputed marker set 
resulted in an increased number of markers reaching LOD-score >3.3 but did not yield higher linkage LOD-
scores for the imputed regions (Table 3). Additionally, we identified suggestive linkage peaks with LOD≥3.0 
on chromosomes 1q42.3, 11q22.1, 12p11.22, 17p13.3 and 18p11.23 (Table 3).  
Markers with significant linkage LOD score show high genotyping quality and heterozygosity (Supplementary 
Table 1). Additional genome-wide linkage analysis with dominant inheritance showed that peaks on 
chromosome 4q25, 6p21-22 and 20q13.2 had genome-wide significant LOD scores in both recessive and 
dominant models (Supplementary Table 2, Supplementary Figure 4). We also performed linkage analysis 
with individuals with T1D and macroalbuminuria and ESRD as affected and individuals with normal AER as 
controls. The analysis showed that 3 of 8 significant peaks had a LOD-score ≥3.3 also with macroalbuminuria 
and ESRD as affected phenotype (Supplementary Table 3).   
HLA Haplotype Imputation and HLA Haplotype-stratified Linkage Analysis 
The HLA-region and in particular the MHC-II haplotypes are the most important genetic risk factors for T1D, 
and a high linkage peak on the HLA-region is well documented for T1D. Therefore, we performed a separate 
linkage analysis for chromosome 6 linkage region with HLA haplotype stratification, based on imputed HLA-
alleles and pedigree types. Based on comparison within a subset of FinnDiane individuals with directly 
genotyped HLA alleles, the imputation of the MHC-II alleles was highly accurate: the prediction of HLA-DQA1 
matched the genotyped allele with 99.1%, HLA-DQB1 with 98.0%, and HLA-DRB1 with 97.2% accuracy (2- or 
4-digit depending on the HLA-typing accuracy). The allele predictions were combined as haplotypes, and the 
MHC-II haplotype risk scores for T1D were based on a chart by Erlich et al (25).  
For 89.2% of the subjects at least one of the two HLA-haplotypes was either DRB1*0301-DQA1*0501-
DQB1*0201 (DR3) or DRB1*0401-DQA1*0301-DQB1*0302 (DR4) (Figure 2). Furthermore, 68.6% of subjects 
had at least one DR4 haplotype, which indicates that the subjects have highly similar HLA-haplotype-based 
genetic risk for T1D. In the stratified analysis including only individuals with the DR4 serotype as cases or 
controls, the linkage remained with LOD-score 7.43 at 6p22 (33.28Mb). 
Sub-pedigree-type Based Linkage Analysis  
In order to find out which pedigree type was the leading contributor to the linkage signals with LOD>3.3, we 
run the linkage analysis separately for different pedigree types. Most of the linkage signals originated form 
the 57 pedigrees concordant for DN, with less signal originating from the 77 discordant pedigrees or from 
the 9 larger pedigrees that included at least 2 concordant individuals and 1 discordant member 
(Supplementary Table 4). As the HLA-region is the main T1D genetic risk component, the trees concordant 
for DN cannot distinguish between the linkage signal originating from DN and T1D. Outside the HLA-region, 
the DN linked regions do not overlap with markers or regions previously linked or associated with T1D 
(Supplementary Table 5). 
In silico Replication of the Linkage Peaks 
We performed an in silico replication for the linkage peaks using the newest JDRF Diabetic Nephropathy 
Collaborative Research Initiative (DNCRI) GWAS for DN with 19,327 individuals (5). Of the regions with 
genome-wide significant linkage, we found significant association on CCSER1 intron on chr4q25 (92,5Mb 
away) with lead SNP rs538044833 (P-value=2.795×10-8). More detailed examination indicated that the 
association was only found in one cohort (The Scottish Diabetes Research Network Type 1 Bioresource, 
N=4,689); thus, this association was not previously reported. The alternative allele of the lead SNP was 
present in 10 cases and 20 controls, yielding a raw odds ratio of 3.0. Furthermore, suggestive associations 
were found in DNCRI at chr2:163.9Mb/2q24.3 (P-value=2.189×10-5), chr2:234.8Mb/2q37.2 (P-
value=2.619×10-5), chr4:88.1Mb/4q21.21 (P-value=6.403×10-6) and chr22:29.1Mb/22q12.1 (P-
value=5.709×10-6) (Figure 3, Supplementary Figure 2, Supplementary Table 6).  
In silico Associations with Gene Expression and DNA Methylation 
We studied whether the lead variants had expression or methylation quantitative trait loci (eQTL; mQTL) 
associations within the flanking region. Of the 11 non-chromosome 6 variants with LOD≥3.3, there were three 
nominal eQTL associations for either glomerular or tubular allele specific expression in the NephQTL 
database: rs10033307-BMP2K (Glomerulus, P-value: 0.022), rs10014992-CCSER1 (Tubule, P-value: 0.011) and 
rs200655-TSHZ2 (Tubule, P-value: 0.043). Furthermore, five SNPs showed significant eQTL associations in 
various tissues in the GTEx database (Supplementary Table 7). In the mQTL database, three DN-linked 
variants at chr4:85.6-91.5Mb showed significant mQTL associations with CpG islands in blood 
(Supplementary Table 8).  
Discussion 
Here, we performed a linkage analysis for DN in 177 computationally inferred and manually curated 
pedigrees using dense genome-wide genotyping chips combined with analytical methods that allow analysis 
across a combination of multiple types of pedigrees. To our knowledge, this is the first genetic linkage study 
for DN or any diabetic complication performed with a dense marker set. We found evidence of genetic linkage 
for DN on multiple novel linked regions on 2q24.3, 2q37.2, 4q21-22, 4q25, 6p21-22, 20q13.2 and 22q12.1.  
Recent GWASs have yielded only few susceptibility loci for DN and replication in other populations have had 
limited success. Out of the newly identified linkage peaks, only few regions overlap with these GWAS loci. 
This is not surprising as the pedigree-based linkage studies are expected to find linked regions within families. 
For example, the best-known susceptibility variants for breast cancer in BRAC1 and BRAC2 genes were 
originally found with linkage studies, long before GWASs with sample sizes of tens or hundreds of thousands 
of individuals were possible (26). Regarding diabetic complications, our recent CACNB2 association with 
diabetic retinopathy was initially discovered by suggestive linkage signal at chromosome 10p12 (27). 
Based on the gene function, expression in kidneys, and associated kidney diseases, we identified plausible 
DN genes located under, or close to these linkage peaks (Table 3). Aside from the linkage peak at the HLA-
region on chromosome 6, the chromosome 4q peak is the widest with markers with significant LOD-scores 
between 79Mb and 91Mb. It remains uncertain whether the peak occurs due to one or multiple signals, but 
long distances between the markers with significant LOD-scores (i.e. rs10033307 at chr4:79.3Mb, rs4129430, 
rs11097033 and rs1482085 at chr4:85.9–86.6Mb and rs10014992 chr4:91.6 Mb) point towards multiple 
separate signals (Supplementary Figure 2 C-E). The 91.0-92.5Mb peak had a genome-wide significant LOD 
score also with a dominant inheritance model (Supplementary Table 2). These markers with significant 
linkage LOD-scores occur on top of FRAS1 (79.0-79.5Mb), ARHGAP24 (86.4-86.9Mb) and CCSER1 (91.0-
92.5Mb), respectively. All of these genes have been associated with kidney function or diseases in previous 
studies (Supplementary Table 9). 
We searched for replication of the linkage loci in a recent GWAS meta-analysis on DKD, and found a genome-
wide significant association with an CCSER1 intronic variant rs538044833 and DKD close to the 4q25 (91.5Mb) 
peak (P-value=2.795×10-8) (Figure 3, Supplementary Figure 2 F, Supplementary Tables 5 and 9) (5). Another 
rare CCSER1 intronic variant rs553908921 was also associated with CKD at genome-wide significant level (P-
value=2.19x10-8) in the recent HUNT study (28). Both associated variants were rare, and in case of 
rs538044833, the association was only observed in the Scottish cohort from the meta-analysis. Furthermore, 
eQTL data suggest that the linkage analysis lead SNP rs10014992 is associated with tubular CCSER1 
expression. While further studies are needed to establish CCSER1 as DN and CKD associated gene, these 
studies strongly support rare variation in CCSER1 as a risk factor for DN.  
The ARHGAP24 gene directly under the linkage peak at 4q22.1 (85.9–86.6Mb) has been associated with 
familial focal segmental glomerulosclerosis (FSGS), a rare familial kidney disease, but not with DN 
(Supplementary Figure 1 D, Supplementary Table 9) (29). Furthermore, the orthologous Q156R mutation 
reduces the capability of mouse Arhgap24 to deactivate Rac1 (29). The Salem et al 2019 meta-analysis also 
showed a suggestive association 1.6Mb from the peak (Supplementary Figure 1 D, Supplementary Table 6).  
Of the SNPs with significant linkage, the chromosome 4q variants account for the majority of the identified 
eQTL and mQTL activity (Supplementary Table 7, Supplementary Table 8). For example, the blood based 
mQTL database shows significant mQTL effect with the ARHGAP24 intronic variant rs1482085 (LOD-
score=3.39) and a CpG-island cg20784207 at birth (P-value=3.30×10-11) and childhood (P-value=3.87×10-10) 
(Supplementary Table 8). Although the associations were not found in the kidney tissue, possibly due to lack 
of large enough eQTL and mQTL databases for the kidney, blood-based associations could also be considered 
interesting due to the microvascular nature of DN.  
Other plausible DN genes under the linkage peaks include AGAP1 on chr2q37.2, GRB14 at 2q24.3 and TSHZ2 
close to 20q13.2, which are associated with insulin resistance, Rac1 activation pathway and renal 
development (Supplementary Table 9). For these linkage peaks outside the chromosome 4, the Salem et al 
2019 meta-analysis showed suggestive associations with DKD for variants on top or close to regions on 2q24.3, 
2q37.2 and 22q12.1 (Supplementary Table 6) (5). 
The HLA region has been identified as a leading genetic factor in some kidney diseases such as the Idiopathic 
membranous nephropathy (30). For DN, previous studies have yielded contradictory findings whether genes 
localized on the HLA region, such as AGER and TNF-α, play a significant role in the development of DN. Of 
note, no significant associations with DN have been found on the HLA region in GWASs.  
In this study, the widest chromosome 6 linkage peak with 165 genome-wide significant markers ranges from 
22.8Mb to 45.1Mb. The region with 13 markers with LOD-score >5 occurred between 33-35Mb (highest with 
LOD 7.3 on 33.5Mb). TNF-α, AGER, as well as the MHC-II genes, are located at 31.5-33Mb. There were also 
several signals throughout the region including a peak at 25Mb, which occurs on top of the LRRC16A gene, 
which has been associated with gout (31). Several studies including our previous linkage analysis showed a 
linkage peak at chromosome 6p21 (8). As this linkage peak occurred on the HLA region and the concordant 
and discordant sibling pairs showed similar haplotype inheritance pattern, it was presumed that the peak 
originated from the genetic risk of T1D, and not from DN. We HLA-stratified the pedigrees by assigning the 
affected/unaffected phenotypes for individuals with high T1D risk HLA DRB1-0401-DQA1-0301-DQB1-0302 
haplotype. This analysis showed an increased LOD-score in the HLA region, when compared to the main 
linkage analysis. We further studied the origin of the signal by running the linkage analyses separately for 
different pedigree types (concordant individuals only, discordant individuals and complex trees). These 
analyses showed that the pedigrees including only concordant affected individuals were responsible for the 
majority of the LOD-score (Supplementary Table 4). Due to the superior power of affected concordant 
individuals only analysis compared to discordant individuals analysis, and relatively small amount of complex 
pedigrees, this may not be surprising. However, as concordant individuals only analysis cannot distinguish 
between DN and T1D, the origin of the peak remains ambiguous.  
In general, the majority of the LOD-scores for the other DN-linked markers originated from the pedigrees 
including only concordant individuals. However, outside the HLA-region, most of these peaks did not co-occur 
with previously found T1D-associated variants or linked regions (Supplementary Table 5). As the genetic 
studies of T1D have been more powerful compared to DN studies due to larger sample sizes, we do not 
expect the non-overlapping linked regions to be novel T1D regions.  
Of note, the HLA-allele imputations performed for the haplotype stratified linkage analysis were significantly 
more accurate than the previous HLA-allele predictions using Illumina 610 K genotyping chip data for 161 
Finnish individuals (32). With the SNP2HLA and HLA*IMP –software and HapMap2 reference panel they 
achieved <20% imputation accuracy for HLA-DRB1-gene, compared to 99.1% for HLA-DQA1, 98.0% for HLA-
DQB1 and 97.2% for HLA-DRB1 in our current study (32). We speculate that the main cause for the drastic 
difference in imputation accuracy between the studies could be due to the different reference panels and 
different genotyping platform used in the studies; i.e. Illumina CoreExome chip includes more exomic variants 
compared to most other genotyping chips, which may also improve the imputation quality for the MHC-II 
alleles. 
Altogether five suggestive linkage peaks had linkage LOD-scores between 3 and 3.3 (Table 3). The 
chromosome 1q42.3 peak with LOD-score of 3.2 is especially notable as it is located between NID1 and 
GPR137B. Previous studies have suggestively associated NID1 with Goodpasture’s syndrome, also called 
glomerular basement membrane disease. Nidogen-1, encoded by NID1, is able to bind to other basement 
membrane proteins such as type IV collagen (33). Rare variants in the COL4A3 gene encoding the α3 subunit 
of type IV collagen have been associated with Alport syndrome, and recently, also a common COL4A3 variant 
was associated with DN on large GWAS done with 19,406 individuals with T1D  (5; 34). This is one example, 
in which a serious, usually monogenic disease is caused by a deleterious rare variant, whereas the risk of a 
complex disease affecting the same tissue type or organ is affected by common variants located in the same 
gene.  
Previous studies have found linked regions on multiple chromosomes, including the most recent findings on 
chromosomes 3q21-25 and 22q11 (7; 8). Our linkage analysis did not result in significant linkage peaks with 
these previously reported ones (Supplementary Table 10, Supplementary Figure 2 C, H). Nevertheless, the 
former 3q21-25 region contained three markers with linkage LOD-score >2.5.  Likewise, a suggestive linkage 
signal with LOD-score of 2.80 was found at 22q11, which could indicate lack of power to detect a genome-
wide signal in this region rather than lack of replication. Of the 440 individuals in the pedigrees in this study, 
175 were also included in our previous study, but most of the previous linkage studies were conducted using 
sparse microsatellite platforms, and the lower linkage LOD-scores could be due to platform differences 
between the SNP microarray and microsatellites (35).  
The study included only a limited amount of pedigrees, and a limited number of individuals within the 
pedigrees. While this has been a common limitation of pedigree-based studies, this study has benefited from 
the development of modern analysis methods that enable studying larger variety of pedigree types together. 
The supporting association evidence for chromosome 4q peak is also based on rare variants, and they could 
be invalidated as more data becomes available. However, finding regions with low frequency and rare 
variants with large effect sizes are main advantage of the linkage studies compared to GWASs. We also note 
that the validity of eQTL associations have met increasing criticism (36). As genotyping and sequencing 
becomes more affordable, and with the rise of large nationwide genotyping and sequencing initiatives, 
studies with larger families, including multiple siblings, cousins etc. will become possible.  
As the Finns have well-documented differences in low-frequency and rare variant patterns compared to 
other European populations, linkage peaks in these Finnish pedigrees do not necessarily exist in pedigrees in 
other countries. Therefore, replication in other Finnish families would be ideal. However, the FinnDiane study 
already covers a substantial proportion of the Finnish individuals with T1D and there is no other T1D study 
cohort with pedigrees and GWAS data available in Finland without significant overlap with the FinnDiane 
study cohort. As only a few individuals included in this study have participated in our WES and WGS studies, 
it is currently not statistically feasible to study variants under the linkage peaks using our sequencing data. 
However, as more individuals will be sequenced, we expect to be able to pinpoint the variants behind these 
signals in our future studies.  
Conclusions 
Our study aimed to identify genetic loci linked to DN in Finnish families including individuals with T1D. The 
results include eight regions with a genome-wide significant linkage signal. The analysis also resulted in peaks 
on top or close to genes, such as ARHGAP24, that have previously been associated with kidney diseases or 
kidney function, but not yet with DN, and a peak on top of CCSER1, where rare variants in two studies have 
been associated with DN and CKD. Although the most conspicuous peak occurred at the HLA-region of 
chromosome 6, it is likely to originate at least in part from the T1D risk. To pinpoint and confirm linked genes, 
more studies are needed. 
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 Table 1 – Number of trees and individuals in the pedigrees included in the linkage analysis 
 
Pedigrees N (trees) Affected Unaffected Unknown 
Concordant sibling pairs 
40 80 0 0 
Discordant sibling pairs 
55 55 55 0 
Sibships 9 14 13 5 
Parent-offspring pairs 
15 20 9 0 
Cousin pairs 7 10 4 0 
Avuncular pairs 
8 12 3 0 
Larger trees 
43 64 44 52 
Affected: Number of affected individuals with DN; Unaffected: number of individuals with normal AER; 












Women (%) 40.4 52.3 <0.0001 
Age (years) 59.5 ± 11.9 57.3 ± 11.0 ns 
BMI (kg.m-2) 26.4 ± 4.6 25.8 ± 3.8 ns 
Age of diabetes onset (years) 12.2 ± 7.5 16.0 ± 9.7 <0.004 
Diabetes duration (years) 36.9 ± 10.8 30.5 ± 11.4 <0.0001 
HbA1c (%) 8.74 ± 1.67 8.23 ± 1.23 <0.05 
Systolic BP (mmHg) 142 ± 21 131 ± 17 <0.0001 
Diastolic BP (mmHg) 81 ± 12 77 ± 8 <0.05 
Albumin excretion rate (mg) 7.99 [4.56-11.955] 157.29 [39.2-955] <0.0001 
eGFR (mL.min-1.1.73m-2) 51 ± 19 97 ± 20 <0.0001 
Micro/Macro/ESRD (n) 78/85/92 - -  
Albumin excretion rate (AER) is presented as median and interquartile range 
 




N markers with LOD-score ≥3.3 (Imputed*) Noteworthy nearby genes 
Genome-wide significant linkage peaks 
2q24.3 3.31 (3.4) 1 (5) 
GRB14 - Insulin resistance, fat distribution, BMI 
(37) 
2q37.2 3.63 (3.7) 1 (20) AGAP1 
4q21.21 3.62 1 
FRAS1 - familial Fraser syndrome, kidney 
function and development (38; 39) 
4q22 3.80 (3.9) 2 (93) 
ARHGAP24 – FSGS (29), PTPN13 – Diabetic 
nephropathy (3)  
4q25 3.41 (3.6) 1 (41) CCSER1 
6p21-22 7.42 165  HLA-region 
20q13.2 3.58 (3.4) 2 (2) 
TSHZ2 - renal pelvis development in human and 
mice (40) 
22q12.1 3.63 (5.1) 2 (8)  
Suggestive linkage peaks 
1q42.3 3.25 1 
NID1 – encodes GBM protein nidogen, plausible 
associations to GBM diseases (41) 
11q22.1 3.1 1  
12p11.22 3.28 3  
17p13.3 3.29 1  
18p11.23 3.16 1  
*Linkage LOD-scores and number of markers with LOD-score ≥3.3 are given for the directly genotyped data, and in parentheses, for imputed data.  
 
 
Figure 1 - Manhattan plot of genome-wide linkage analysis. The plot shows results of genome-wide 
linkage analysis LOD scores. The analysis showed linkage peaks with genome-wide significant LOD scores > 
3.3 on chromosomes 2q24.3, 2q37.2, 4q21 - 22, 4q25, 6p21-22, 20q13.2 and 22q12.1. The highest and 
widest peak occurs on chromosome 6p HLA region.
 
Figure 2 - Imputed HLA haplotype and genotype frequencies for patients in pedigrees. The HLA alleles 
were imputed using SNP2HLA software and T1DGC reference panel, and then combined into HLA-
haplotypes and genotypes. A - shows that majority of haplotypes were high T1D risk DR3 or DR4 
haplotypes. B - Moreover, more than 80% of individuals has either one or two DR4, which further highlights 
the homogenic genetic risk for T1D on this cohort.
 
Figure 3 - LocusZoom regional association plot of 4q25, showing the significant linkage and association 
signals. The y-axis indicates the -log10(p-values), instead of LOD scores, for both linkage and association 
results. The purple diamonds show DN linkage P-value for the lead SNP in our current linkage study, 
whereas the red circles with rs-numbers display association P-values from Salem et al. 2019. The remaining 
SNPs are coloured according to their r2 correlation with the lead SNP. 
